Drug Approval | October 04, 2021
Lilly to transfer rights of two diabetes drugs to Cipla in India
Lilly will continue to maintain its existing operating model for the remaining portfolio of products
Lilly will continue to maintain its existing operating model for the remaining portfolio of products
The company plans to submit the IND application by the end of 2021
This one-of-a-kind innovation challenge is aimed at addressing the challenges faced by healthcare providers in digital technology adoption
The acquisition complements and strengthens Merck’s cardiovascular pipeline
These pouches, manufactured at UFlex India plant, will be exported to American markets and will be majorly used for packing edible products
The CAC solution cleared by the U.S. FDA analyses already existing non-gated CT scans and quantifies the coronary artery calcium in order to identify, stratify, and facilitate treatment pathways for patients with cardiovascular disease
One of the key factors driving the market growth is the rise in the occurrence of chronic cardiovascular diseases such as heart failure and coronary artery disease: Valuates Reports
As part of this strategic partnership, LTI with its digital, technical and life sciences domain capabilities, will help accelerate joint go-to-market pursuits and faster deployment for Clinpal Adopters
The investment will increase SpeeDx internal capacity to scale up manufacturing
saRNA is a new platform for the development of medicines and vaccines which uses similar technology to mRNA but with the added ability to self-amplify, thereby expressing proteins for longer, resulting in higher protein levels per dose level
Subscribe To Our Newsletter & Stay Updated
